Clinical efficacy and safety of combination of abraxane and trastuzumab in treatment of recurrent ovarian cancer

ABSTRACT

Present research work is carried out to compare the clinical efficacy and adverse reactions between combined medication of abraxane and trastuzumab and single medication of trastuzumab in treatment of ovarian cancer. A total of 80 recurrent ovarian cancer patients in Stage III B or IV confirmed by histopathological examination and/or cytological examination were enrolled in this study and divided into two groups, i.e. the combined medication group [n=37] and the single medication group [n=43]. Patients in two groups underwent therapy for 4 cycles to evaluate the short-term efficacy and adverse reactions of these two methods. The control rates of the combined medication group and the single medication group were 86.4% and 81.4%, respectively, while the partial response rates were 45.9% and 44.2%, respectively. As for the overall survival [OS], the OS in the single medication group was 7.0 months, while that in the combined medication group was 7.3 months [p=0.63]. Incidence of neutropenia in the single and combined medication groups were respectively 51.2% and 40.5%, while the incidence rates of leukopenia in Stage III or IV were 44.2% and 24.3%, respectively [p<0.001] and the differences between two groups were statistically significant. Also, comparison of the incidence rates of thrombocytopenia between the single [53.5%] and combined [23.6%] medication groups showed statistical significance. With promising efficacy, few adverse reaction and high safety, combined medication of abraxane and trastuzumab is more applicable to the treatment of recurrent ovarian cancer